Generating AI analysis...
Revenue
$35.69B
-0.74% YoY
EPS (Basic)
$2.93
++165.84% YoY
Evidence Layer
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $35.69B | $35.96B | -0.74% |
Cost of Revenue | $9.84B | $9.16B | +7.46% |
Net Income | $5.97B | $-9.02B | +166.15% |
EPS (Basic) | $2.93 | $-4.45 | +165.84% |
EPS (Diluted) | $2.93 | $-4.45 | +165.84% |
R&D Expense | $7.37B | $7.97B | -7.57% |
SG&A Expense | $5.09B | $6.28B | -18.99% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $96.89B | $93.67B | +3.44% |
Current Assets | $35.63B | $28.07B | +26.91% |
Total Liabilities | $78.29B | $76.47B | +2.38% |
Current Liabilities | $28.14B | $22.64B | +24.29% |
Stockholders' Equity | $18.55B | $17.14B | +8.23% |
Cash & Equivalents | $15.73B | $7.89B | +99.32% |
Long-Term Debt | $48.72B | $49.55B | -1.68% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $12.18B | $10.75B | +13.31% |
Investing Cash Flow | $-2.67B | $-21.16B | +87.36% |
Financing Cash Flow | $-4.32B | $6.77B | -163.81% |
Dividends Paid | $3.78B | $3.65B | +3.79% |
D&A | $3.03B | $7.72B | -60.70% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 16.7% | — | — |
ROE | 32.2% | — | — |
ROA | 6.2% | — | — |
Current Ratio | $1.266 | — | — |
Debt to Equity | $4.22 | — | — |
Other companies in Pharmaceuticals